Bionomics Limited (NASDAQ:BNOX) Short Interest Update

Bionomics Limited (NASDAQ:BNOXGet Free Report) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 13,800 shares, a decline of 81.1% from the September 30th total of 73,000 shares. Based on an average trading volume of 626,600 shares, the short-interest ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Bionomics in a research report on Thursday, August 1st.

Read Our Latest Stock Report on Bionomics

Bionomics Stock Down 31.5 %

Bionomics stock traded down $0.11 during trading on Friday, reaching $0.25. 4,017,426 shares of the company’s stock were exchanged, compared to its average volume of 541,273. The company’s 50-day moving average is $0.50 and its two-hundred day moving average is $0.71. Bionomics has a 52-week low of $0.23 and a 52-week high of $3.03.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC purchased a new stake in Bionomics Limited (NASDAQ:BNOXFree Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned about 15.03% of Bionomics as of its most recent filing with the Securities and Exchange Commission (SEC). 15.90% of the stock is currently owned by institutional investors.

Bionomics Company Profile

(Get Free Report)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

Read More

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.